State of New Jersey Common Pension Fund D Has $1.97 Million Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)

State of New Jersey Common Pension Fund D reduced its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 63.3% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 13,070 shares of the company’s stock after selling 22,528 shares during the period. State of New Jersey Common Pension Fund D’s holdings in TransMedics Group were worth $1,969,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Fidelis Capital Partners LLC acquired a new stake in shares of TransMedics Group during the first quarter worth $35,000. International Assets Investment Management LLC acquired a new stake in shares of TransMedics Group during the second quarter worth $47,000. J.Safra Asset Management Corp grew its stake in shares of TransMedics Group by 649.2% during the second quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock worth $67,000 after purchasing an additional 383 shares during the period. Signaturefd LLC grew its stake in shares of TransMedics Group by 26.6% during the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after purchasing an additional 93 shares during the period. Finally, Entropy Technologies LP acquired a new stake in shares of TransMedics Group during the first quarter worth $201,000. 99.67% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Anil P. Ranganath sold 4,289 shares of the company’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $152.20, for a total transaction of $652,785.80. Following the sale, the insider now owns 8,893 shares in the company, valued at $1,353,514.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the sale, the chief executive officer now owns 61,643 shares in the company, valued at $9,457,269.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Anil P. Ranganath sold 4,289 shares of the company’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $152.20, for a total value of $652,785.80. Following the sale, the insider now owns 8,893 shares in the company, valued at approximately $1,353,514.60. The disclosure for this sale can be found here. Insiders have sold a total of 61,247 shares of company stock worth $9,650,880 over the last three months. Corporate insiders own 7.00% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on TMDX shares. Stephens lifted their price objective on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Canaccord Genuity Group lifted their price objective on TransMedics Group from $117.00 to $169.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. Oppenheimer lifted their target price on TransMedics Group from $125.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, August 1st. Cantor Fitzgerald began coverage on TransMedics Group in a report on Thursday, June 6th. They set an “overweight” rating and a $161.00 target price on the stock. Finally, Needham & Company LLC began coverage on TransMedics Group in a report on Wednesday, August 21st. They set a “buy” rating and a $208.00 target price on the stock. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $171.44.

TransMedics Group Stock Performance

Shares of TransMedics Group stock opened at $165.00 on Friday. The firm has a market cap of $5.43 billion, a price-to-earnings ratio of -485.29 and a beta of 1.99. The stock’s 50-day moving average is $155.65 and its 200-day moving average is $129.31. TransMedics Group, Inc. has a one year low of $36.42 and a one year high of $177.37. The company has a debt-to-equity ratio of 2.67, a current ratio of 9.37 and a quick ratio of 8.48.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $0.35 EPS for the quarter, beating analysts’ consensus estimates of $0.21 by $0.14. The company had revenue of $114.30 million for the quarter, compared to analyst estimates of $98.84 million. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The company’s quarterly revenue was up 117.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.03) earnings per share. Equities analysts predict that TransMedics Group, Inc. will post 1.23 earnings per share for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.